Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Pirin delocalization in melanoma progression identified by high content immuno-detection based approaches.

Licciulli S, Luise C, Zanardi A, Giorgetti L, Viale G, Lanfrancone L, Carbone R, Alcalay M.

BMC Cell Biol. 2010 Jan 20;11:5. doi: 10.1186/1471-2121-11-5.

2.

Identification of pirin, a novel highly conserved nuclear protein.

Wendler WM, Kremmer E, Förster R, Winnacker EL.

J Biol Chem. 1997 Mar 28;272(13):8482-9.

3.

Pirin inhibits cellular senescence in melanocytic cells.

Licciulli S, Luise C, Scafetta G, Capra M, Giardina G, Nuciforo P, Bosari S, Viale G, Mazzarol G, Tonelli C, Lanfrancone L, Alcalay M.

Am J Pathol. 2011 May;178(5):2397-406. doi: 10.1016/j.ajpath.2011.01.019.

4.

Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.

Nazarian RM, Prieto VG, Elder DE, Duncan LM.

J Cutan Pathol. 2010 Apr;37 Suppl 1:41-7. doi: 10.1111/j.1600-0560.2010.01505.x.

PMID:
20482674
5.

Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.

Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, Lazar AJ, Shen SS, Zhang PS, Reed JA, Gershenwald JE, Raz A, Bar-Eli M.

Clin Cancer Res. 2006 Nov 15;12(22):6709-15.

6.
7.

Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.

Perry BN, Cohen C, Govindarajan B, Cotsonis G, Arbiser JL.

Arch Dermatol. 2006 Aug;142(8):1031-4.

PMID:
16924053
8.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer..

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
9.

Association of insulin-like growth factor binding protein-3 expression with melanoma progression.

Xi Y, Nakajima G, Hamil T, Fodstad O, Riker A, Ju J.

Mol Cancer Ther. 2006 Dec;5(12):3078-84.

10.

MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines.

Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, Peng H, Ivanov AV, Simpson AJ, Longley BJ.

Cancer Res. 2007 Oct 15;67(20):9954-62.

11.

Functional proteomic analysis of melanoma progression.

Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, Everett AD, Fukasawa K, Norris DA, Ahn NG, Resing KA.

Cancer Res. 2003 Oct 15;63(20):6716-25.

12.

WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis.

Garrido-Ruiz MC, Rodriguez-Pinilla SM, Pérez-Gómez B, Rodriguez-Peralto JL.

J Cutan Pathol. 2010 May;37(5):542-8. doi: 10.1111/j.1600-0560.2009.01379.x.

PMID:
19638168
13.

Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.

Wang Y, Dai DL, Martinka M, Li G.

Clin Cancer Res. 2007 Jul 15;13(14):4111-6.

14.

Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress.

Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, Baldi F, Rossiello L, Dell'Anna ML, Mastrofrancesco A, Maresca V, Flori E, Natali PG, Picardo M, Paggi MG.

Clin Cancer Res. 2005 May 1;11(9):3175-83.

15.

Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.

Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB.

Gene. 2001 Nov 14;279(1):17-31.

PMID:
11722842
16.

Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.

Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M.

Clin Cancer Res. 2007 Feb 1;13(3):806-15.

17.

HER3 is a determinant for poor prognosis in melanoma.

Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A.

Clin Cancer Res. 2008 Aug 15;14(16):5188-97. doi: 10.1158/1078-0432.CCR-08-0186.

18.

Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma.

Hau P, Ruemmele P, Kunz-Schughart LA, Doerfelt A, Hirschmann B, Lohmeier A, Koch H, Mueller A, Bogdahn U, Bosserhoff AK.

Oncol Rep. 2004 Dec;12(6):1355-64.

PMID:
15547763
19.

Crystal structure of human pirin: an iron-binding nuclear protein and transcription cofactor.

Pang H, Bartlam M, Zeng Q, Miyatake H, Hisano T, Miki K, Wong LL, Gao GF, Rao Z.

J Biol Chem. 2004 Jan 9;279(2):1491-8.

20.

A high percentage of skin melanoma cells expresses SPANX proteins.

Salemi M, Calogero AE, Vicari E, Migliore E, Zaccarello G, Cosentino A, Amore M, Tricoli D, Castiglione R, Bosco P, Rappazzo G.

Am J Dermatopathol. 2009 Apr;31(2):182-6. doi: 10.1097/DAD.0b013e3181978d6f.

PMID:
19318807
Items per page

Supplemental Content

Support Center